Kailera Therapeutics, Inc.

Kailera Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for obesity and related metabolic conditions. The company's pipeline includes injectable peptides, oral peptides, and oral small molecules. Its lead program is KAI-9531, an injectable GLP-1/GIP receptor dual agonist. Additionally, Kailera is developing KAI-7535, an oral small molecule GLP-1 receptor agonist, and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. The company holds exclusive global development and commercialization rights for four metabolic disease assets outside of Greater China, with therapies delivered through both oral and injectable formulations.

Kailera Therapeutics is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol KLRA. The company's stock trades in US dollars (USD). As a US-based company listed on a major US exchange, its financial reporting and share pricing are denominated in USD, making it accessible to investors trading on US markets.

Kailera Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biopharmaceutical company, it focuses on researching and developing novel therapies for obesity and related conditions. Biotechnology companies like Kailera typically engage in drug discovery, preclinical studies, and clinical trials to bring new treatments to market, often with a high degree of scientific innovation and regulatory oversight.

Kailera Therapeutics is headquartered in Waltham, Massachusetts, United States. The company was founded in 2024 and operates primarily in the US. While its headquarters are in Massachusetts, its development and commercialization rights extend globally outside of Greater China, indicating a broad geographic strategy for its metabolic disease assets. The company's therapies are being developed for worldwide markets, with a focus on addressing obesity and related conditions.

Kailera Therapeutics' pipeline includes several promising candidates for obesity and metabolic diseases. The lead program is KAI-9531, an injectable GLP-1/GIP receptor dual agonist designed to target two key hormone receptors involved in appetite and glucose regulation. Another notable candidate is KAI-7535, an oral small molecule GLP-1 receptor agonist, which offers a convenient oral administration route. Additionally, KAI-4729 is an injectable GLP-1/GIP/glucagon receptor tri-agonist, targeting three receptors for enhanced efficacy. The company also holds exclusive rights to four metabolic disease assets from Greater China, covering both oral and injectable formulations.